Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Beam Therapeutics (BEAM) Leases (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Leases for 7 consecutive years, with $100.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Leases fell 3.99% to $100.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $100.7 million, a 3.99% decrease, with the full-year FY2025 number at $100.7 million, down 3.99% from a year prior.
  • Leases was $100.7 million for Q4 2025 at Beam Therapeutics, up from $97.0 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $118.5 million in Q4 2022 to a low of $13.6 million in Q2 2022.
  • A 5-year average of $102.6 million and a median of $105.4 million in 2021 define the central range for Leases.
  • Peak YoY movement for Leases: surged 2442.71% in 2021, then tumbled 87.09% in 2022.
  • Beam Therapeutics' Leases stood at $102.7 million in 2021, then increased by 15.38% to $118.5 million in 2022, then dropped by 4.78% to $112.8 million in 2023, then dropped by 7.07% to $104.9 million in 2024, then dropped by 3.99% to $100.7 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Leases are $100.7 million (Q4 2025), $97.0 million (Q3 2025), and $99.6 million (Q2 2025).